Chemokine Therapeutics announces preliminary results of CTCE-9908 Phase Ib/II clinical trial in late stage cancer patients



    TSX: CTI
    OTCBB: CHKT

    VANCOUVER, March 12 /CNW/ - Chemokine Therapeutics Corp. ("Chemokine
Therapeutics" or the "Company") (TSX:CTI, OTCBB:CHKT), a biotechnology company
developing chemokine-based therapies to treat cancer, blood disorders, and
vascular disease today announced positive preliminary data and the successful
completion of the dose-escalation portion of its Phase Ib/II clinical trial
for CTCE-9908, the Company's anti-cancer drug candidate. No dose limiting
toxicities were observed in any of the cancer patients and two out of three
patients with ovarian cancer responded positively and exhibited stable
disease.
    Chemokine Therapeutics will now proceed with the remaining portion of the
clinical trial in which up to twenty additional patients will be treated at
5mg/kg/day. The Company expects to enroll the remainder of the patients and
complete the current trial by the end of Q3 2007. The Company has also
accelerated its efforts to initiate a large Phase II program in the U.S. by
the end of 2007. Accordingly, a pre-IND meeting has been scheduled with the
FDA to discuss the Company's future clinical trial program.
    "We are very pleased that no dose-limiting toxicities were observed in
the first part of the trial and encouraged by the positive outcome in the
small group of ovarian cancer patients," said Dr. Hassan Salari, Chemokine
Therapeutics President and CEO. "It is quite remarkable to see clinical
evidence of efficacy considering these patients have exhausted every
therapeutic avenue. We are now looking to rapidly expand the number of
patients in Phase II clinical trials of CTCE-9908 to examine the potential
broader applicability of this novel oncology drug in the treatment of cancer
patients."
    The primary purpose of this study is dose-selection and evaluation of
safety and tolerability of CTCE-9908. CTCE-9908 is administered via a
30-minute infusion on weekdays over a treatment period of four consecutive
weeks (20 doses in total), with each subject receiving a dose level defined by
the dose-escalation schedule. The Phase Ib/II trial includes subjects with
advanced tumors refractory to the current standard of care. The trial enrolled
patients at the Clinical Research Unit of both the Juravinski Cancer Center
(Hamilton, Ontario, Canada) and the Sir Mortimer B. Davis - Jewish General
Hospital (Montreal, Quebec, Canada).
    During the dose-escalation portion of the Phase Ib/II trial, a total of
ten patients were treated with CTCE-9908 with doses ranging from 0.25 to
5 mg/kg/day. Six of the patients received the expected 20 dose course of
treatment. Eight of the ten patients received doses within the expected
therapeutic range of 1 to 5 mg/kg/day. Among these patients, there were three
with late stage ovarian cancer. Two of the three ovarian cancer patients
demonstrated stable disease using the Response Evaluation Criteria in Solid
Tumors (RECIST) when comparing the size of target tumors at baseline before
treatment with CTCE-9908 to the assessment performed at completion of therapy.
One of these patients defined as stable disease had an overall decrease tumour
mass with an associated decrease of greater than 50% in CA-125 after 9 doses
of CTCE-9908 while receiving no other therapy. CA-125 is an ovarian cancer
biomarker that is used to monitor disease status and response to treatment.
    The daily infusions at all dose levels were generally well tolerated with
one subject at the 5mg/kg dose level experiencing moderate localized phlebitis
that was attributed to the study drug. No serious adverse events were recorded
that were attributed to the use of CTCE-9908 after 20 or more doses.

    About CTCE-9908
    CTCE-9908 is a peptide analog of the Chemokine SDF-1, and an antagonist
of its receptor, CXCR4. SDF-1 is the only known naturally occurring chemokine
that binds to CXCR4, which is present on many cancer cells. This binding
process is believed to be critical in angiogenesis and in the metastasis (or
spread) of cancer cells to distant locations in the body, where they form new
tumors. Approximately 90% of cancer deaths are due to metastasis. We believe
that CTCE-9908 interferes with the metastatic process of cancers by both
preventing them to spread and blocking the blood supply to the cancer cells.

    About Chemokine Therapeutics Corp. (TSX: CTI, OTCBB: CHKT)
    Chemokine Therapeutics is a product-focused biotechnology company
developing drugs in the field of chemokines. Chemokines are a class of
signaling proteins which play a critical role in the growth, differentiation,
and maturation of cells necessary for fighting infection as well as tissue
repair and regeneration. Chemokines also have an important role in cancer
metastasis and growth. Chemokine Therapeutics is a leader in research in the
field of chemokines and has several products in various stages of development.

    Safe Harbor Statement under the U.S. Private Securities Litigation Reform
Act of 1995: Statements in this document regarding managements' future
expectations, beliefs, goals, plans or prospects constitute forward-looking
statements that involve risks and uncertainties, which may cause actual
results to differ materially from the statements made. For this purpose, any
statements that are contained herein that are not statements of historical
fact may be deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes", "anticipates", "plans", "intends", "will",
"should", "expects", "projects", and similar expressions are intended to
identify forward-looking statements. You are cautioned that such statements
are subject to a multitude of risks and uncertainties that could cause actual
results, future circumstances, or events to differ materially from those
projected in the forward-looking statements. These risks include, but are not
limited to, those associated with the success of research and development
programs, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, financing capability, the
potential dilutive effects of any financing, reliance on subcontractors and
key personnel and other risks detailed from time-to-time in the Company's
public disclosure documents and other filings with the U.S. Securities and
Exchange Commission and Canadian securities regulatory authorities.
Forward-looking statements are made as of the date hereof, and the Company
disclaims any intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.





For further information:

For further information: Chemokine Therapeutics Corp., Mr. Don Evans,
Director of Public Relations, Phone: (604) 822-0305 or 1-888-822-0305, Fax:
(604) 822-0302, E-mail: devans@chemokine.net, Internet: www.chemokine.net;
Equicom Group, Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext.
233, Fax: (416) 815-0080, E-mail: jlongo@equicomgroup.com

Organization Profile

CHEMOKINE THERAPEUTICS CORP.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890